UK government pays for 90 million doses of further COVID-19 vaccines

14 August 2020

The UK government has secured millions more doses of COVID-19 vaccine candidates for the British population.

New in-principle agreements have secured 60 million doses of a vaccine being developed by US biotech Novavax (Nasdaq: NVAX) and 30 million doses of a candidate from the Johnson & Johnson (NYSE: JNJ) unit Janssen.

Ministers have also agreed in principle to co-fund a ground-breaking global clinical study of the Janssen vaccine. The next phase of trials is expected to begin later this year to look at whether providing two doses provides long-term protection against coronavirus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK